Answers · IP Strategy & Portfolio
Should we prioritize patent quality or quantity?
Updated June 2026
The short answer
Quality, for almost every company holding fewer than a few hundred patent families. One patent whose claims demonstrably read on a competitor's product is worth more than a dozen that read on nothing anyone ships, and weak patents cost nearly as much as strong ones to obtain and maintain.
The exceptions are real but specific: dense cross-licensing fields such as semiconductors, telecom, and automotive, where portfolio mass functions as negotiating currency. If that is your field you eventually need both, and the order is still quality first.
What quality means in a patent
A high-quality patent has claims that read on products people actually ship, describes infringement you could detect from outside the infringer's building, covers the alternative implementations a competitor would reach for, and rests on a specification complete enough to survive validity scrutiny. Quality is set early: most of it is determined by how well the invention was understood and documented before counsel ever drafted a claim.
That is why disclosure quality is the highest-leverage input. In our experience across thousands of filings, strong disclosures can cut prosecution time by 30 to 40 percent, and the same completeness that speeds prosecution is what produces claims worth enforcing.
Where volume genuinely matters
In sectors where every major player ships products that touch thousands of patents, companies cross-license portfolios rather than litigate them, and the size of your stack affects the terms. Standards-relevant technologies behave similarly. Large counts also carry deterrent weight: a competitor considering an assertion against a company holding a thousand patents has to price in the counter-assertion.
Notice what those situations share: the volume is doing a negotiating job, and it only works if enough of the underlying patents would survive a hard look. Volume built from weak filings is a bluff that sophisticated opponents call.
Quality and quantity come from the same pipeline
The framing of a trade-off is mostly false at the pipeline level. The winning pattern we see is harvest broadly, file selectively: surface a large pool of candidate inventions, then spend filing budget only on the ones that score well on commercial value, detectability, and durability. One Fortune 500 medical device client generated nearly 150 invention concepts in a single ipScan engagement, filed more than 80 applications from them, and achieved a 98 percent issuance rate. The volume came from capture; the quality came from selection and disclosure depth.
A company that only generates five ideas a year has no selection to do. Fix the top of the funnel and the quality-versus-quantity question mostly answers itself.
Related questions
How do we assess the quality of the portfolio we already have?
Map every family to current products and revenue, check whether the independent claims still read on what the market ships, and benchmark coverage against named competitors. That audit routinely finds both dead weight to prune and gaps worth filing into.
Do acquirers count patents or read them?
Both, in that order. Counts shape first impressions; diligence reads the claims. Deals reprice when the reading disappoints, which is why a smaller portfolio that maps cleanly to the acquired revenue outperforms a padded one.
Is a high allowance rate proof of quality?
Only partially. Allowance can also mean the claims were narrowed until the examiner had nothing left to reject, which produces issued patents too narrow to matter. Quality shows in what the issued claims cover, never in the issuance event itself.
Can an existing weak portfolio be improved?
Often, yes. Pending applications can be redirected through continuation practice by your counsel, weak families can be pruned to free budget, and new filings can be aimed at the gaps. Improvement is a portfolio-management exercise rather than a restart.
Raise the quality bar before the next filing
If the next application is already in motion, the disclosure behind it is the place to invest. We can scope a review or a disclosure program in a free call.
Talk with Our TeamRelated
ipCapital Group is a consultancy, not a law firm, and nothing on this page is legal advice. Dollar figures on this page are typical market ranges for professional IP services, drawn from published sources and industry experience across a variety of providers. They are not an ipCG quote or rate card; every ipCG engagement is individually scoped and priced. See how our pricing works.